Indaptus Therapeutics, Inc. (INDP): Form 8-K filed 2026-11-13

Accepted by EDGAR: 2026-11-13 16:30 ET
Event date: 2026-11-13
Accession no.: 0001493152-26-051749
Original filing: SEC EDGAR filing index

AI summary of the filing text. It can contain mistakes; the original filing is authoritative.

Indaptus reports third-quarter 2026 results and private placement completion

Indaptus reported third-quarter 2026 net loss of approximately $1.0 million, compared with approximately $3.0 million a year earlier. It disclosed completion of a private placement for approximately $24.0 million in aggregate gross proceeds and described early-stage evaluation of a potential device for certain sleep-related conditions.

Third-quarter 2026 net loss was approximately $1.0 million, compared with approximately $3.0 million for the same period in 2025.
Cash, cash equivalents and short-term investments totaled approximately $30.6 million as of September 30, 2026.
A private placement for aggregate gross proceeds of approximately $24.0 million closed on October 16, 2026.
The company is evaluating a potential neurotechnology and neural-network-based device for certain sleep-related conditions.

earningsequity offeringproduct

Items reported

Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed".
Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.

Documents

Type	Description	Document
8-K	8-K	form8-k.htm
EX-99.1	EX-99.1	ex99-1.htm

The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.